Table 1.
Therapeutic effects of functional inhibitors targeting ASM in neurological pathologies.
| Name | Target tissue or cell | Disease | Mouse model | Therapeutic effects | Ref |
|---|---|---|---|---|---|
| Amitriptyline | Brain | Major depression |
ASM-transgenic mice Stress-induced mice |
Hippocampal neuronal loss ↓ Hippocampal neurogenesis ↑ Behavioral dysfunction ↓ |
44,92 |
| Brain | Ischemic stroke | Focal cerebral ischemia-induced mice |
Leukocyte brain infiltration ↓ Angiogenesis ↑ Neuronal survival ↑ |
93 | |
|
Brain Blood |
Alzheimer’s disease | APP/PS1 |
Aβ accumulation ↓ Abnormal neuronal autophagy ↓ Memory impairment ↓ |
25,43 | |
|
BBB-ECs Blood |
Aging | 20-month-old WT mice |
BBB disruption ↓ Neuronal loss ↓ Memory impairment ↓ |
24 | |
| Fluoxetine | Brain | Major depression |
ASM-transgenic mice Stress-induced mice |
Hippocampal neuronal loss ↓ Hippocampal neurogenesis ↑ Behavioral dysfunction ↓ |
44,92 |
| Brain | Ischemic stroke | Focal cerebral ischemia-induced mice |
Angiogenesis ↑ Motor-coordination recovery ↑ |
93 | |
| Imipramine | Brain | Traumatic brain injury | TBI-induced rat |
Hippocampal neuronal death ↓ Neuroinflammation ↓ Cognitive dysfunction ↓ |
94 |